Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Apple Restores Telegram to App Store After Content Policy Violation 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
 2018 Annual Meeting - EconoTimes)
RANCHO CORDOVA, Calif., March 28, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) today announced that two late-breaking abstracts involving the use of Cesca’s X-Series™ technologies for cell processing have been accepted for presentation as posters at the ISCT 2018 Annual Meeting, which is being held May 2-5, 2018 at the Palais des Congrès de Montréal in Montreal, Québec. Details of the poster presentations are as follows:
Abstract 2963114: Novel buoyancy based cell selection: X-BACS™ Technology
Poster number/abstract ID number: 380
Poster Session 2: May 4, 2018, 5:00-6:30PM
Abstract 2963911: Quick and easy method for removal of DMSO from thawed cellular products
Poster number/abstract ID number: 381
Poster Session 2: May 4, 2018, 5:00-6:30PM
About the International Society for Cellular Therapy (ISCT) Annual Meeting
ISCT is a global society of clinicians, regulators, technologists, and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients' lives. ISCT members gain access to an influential global community of peers, experts, and organizations invested in cell therapy. ISCT offers a unique collaboration between academia, regulatory bodies, and industry partners in cell therapy translation.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
